Aubagio

Aubagio (teriflunomide) is an oral disease-modifying therapy (DMT) used to treat adults and children (aged 10+) with relapsing forms of multiple sclerosis (MS), including relapsing-remitting MS (RRMS), active secondary progressive MS (SPMS), and clinically isolated syndrome (CIS). It works by reducing the number of active lymphocytes, thereby lowering relapse rates and slowing disability progression.